Sugi Predict

Sugi Predict / Compounds / SCHEMBL2864664

SCHEMBL2864664

SCHEMBL2864664

COc1cc2c(cc1O)[nH]c(=O)c1c(N)n(-c3ccc(Oc4ccccc4)cc3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP2 O95551 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.39
▸ FAAH O00519 1/20 0.39
▸ MGLL Q99685 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ APP P05067 1/20 0.39
▸ ADORA3 P0DMS8 3/20 0.38
▸ ADORA1 P30542 2/20 0.38
▸ EGFR P00533 1/20 0.38
▸ NTRK1 P04629 3/20 0.38
▸ IGF1R P08069 3/20 0.38
▸ FGFR1 P11362 3/20 0.38
▸ NTRK2 Q16620 3/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ LCK P06239 1/20 0.38
▸ FYN P06241 1/20 0.38
▸ LYN P07948 1/20 0.38
▸ SRC P12931 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2862123 0.92 ALDH1A1 (0.44) TDP2ALDH1A1FAAHMGLLKDM4E
SCHEMBL2868582 0.85 ADORA3 (0.47) TDP2ALDH1A1FAAHMGLLKDM4E
SCHEMBL2867124 0.84 TDP2 (0.47) TDP2ADORA3ADORA1NTRK1IGF1R
SCHEMBL2868711 0.84 TDP2 (0.47) TDP2FAAHMGLLKDM4EHSD17B10
SCHEMBL2862539 0.83 TDP2 (0.44) TDP2ALDH1A1FAAHMGLLADORA3
SCHEMBL2865010 0.82 MGLL (0.43) TDP2ALDH1A1FAAHMGLLKDM4E
SCHEMBL2861115 0.82 ADORA3 (0.40) TDP2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2870382 0.81 BTK (0.47) TDP2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2867465 0.80 EGFR (0.37) ALDH1A1KDM4EHPGDHSD17B10ADORA3
SCHEMBL2865064 0.80 BTK (0.50) TDP2ADORA3ADORA1NTRK1IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 TDP2 3548/4885ALDH1A1 2391/4885FAAH 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.